We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Raloxifene (Evista)is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Raloxifene (Evista) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 1999–2013 with a typical study size of 7,705 participants.
Based on 8 studies · 1 meta-analysis · 5 RCTs · 50,509 total participants
Confidence
HighBy outcome
Raloxifene (Evista) has an evidence score of 5.3/10 — emerging evidence based on 8 indexed studies, including 1 meta-analysis. A second-generation selective estrogen receptor modulator (SERM) approved for postmenopausal osteoporosis and for reducing the risk of invasive breast cancer in high-risk and osteoporotic postmenopausal women. In the pivotal MORE trial it cut vertebral-fracture risk and reduced invasive (largely ER-positive) breast cancer by ~70%; CORE extended the breast-cancer benefit to 8 years, and the STAR trial showed it roughly matched tamoxifen for invasive-breast-cancer prevention with less uterine cancer. It is used OFF-LABEL by some men for gynecomastia (a small pediatric series found it shrank pubertal breast tissue). The honest limits are non-negotiable: the RUTH trial found NO reduction in coronary events but a significant increase in FATAL STROKE and venous thromboembolism, raloxifene does NOT reduce hip or non-vertebral fractures, and it commonly causes hot flushes and leg cramps. It is NOT a supplement and NOT a longevity drug. Representative study: PMID 23639488.
Last reviewed June 2026 · evidence from 8 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Raloxifene hydrochloride (Evista) — a benzothiophene SERM
A second-generation selective estrogen receptor modulator (SERM) approved for postmenopausal osteoporosis and for reducing the risk of invasive breast cancer in high-risk and osteoporotic postmenopausal women. In the pivotal MORE trial it cut vertebral-fracture risk and reduced invasive (largely ER-positive) breast cancer by ~70%; CORE extended the breast-cancer benefit to 8 years, and the STAR trial showed it roughly matched tamoxifen for invasive-breast-cancer prevention with less uterine cancer. It is used OFF-LABEL by some men for gynecomastia (a small pediatric series found it shrank pubertal breast tissue). The honest limits are non-negotiable: the RUTH trial found NO reduction in coronary events but a significant increase in FATAL STROKE and venous thromboembolism, raloxifene does NOT reduce hip or non-vertebral fractures, and it commonly causes hot flushes and leg cramps. It is NOT a supplement and NOT a longevity drug.
Raloxifene has strong, randomized, outcome-level evidence for its APPROVED uses: the pivotal MORE trial cut vertebral-fracture risk and reduced invasive (ER-positive) breast cancer by ~70%, CORE extended the breast-cancer benefit to 8 years, the STAR trial showed it roughly matched tamoxifen for preventing invasive breast cancer with less uterine cancer and fewer clots, and a 9-trial individual-participant SERM meta-analysis confirms a ~38% breast-cancer reduction over 10 years. The score is held in the emerging band by mandatory, well-documented limits: the RUTH trial found NO reduction in coronary events but a SIGNIFICANT increase in FATAL STROKE (HR 1.49) and venous thromboembolism (HR 1.44); raloxifene does NOT reduce hip or non-vertebral fractures; and it commonly causes hot flushes and leg cramps. The off-label male/gynecomastia use is poorly evidenced (a small retrospective pediatric series only). Strong for vertebral fracture and breast-cancer risk reduction; real clot/stroke risk and no cardiovascular or hip-fracture benefit. NOT a supplement, NOT a longevity drug.
Raloxifene hydrochloride (Evista) is a second-generation, benzothiophene selective estrogen receptor modulator (SERM) — a drug that acts as an estrogen AGONIST in some tissues (notably bone, where it preserves bone mineral density) and an estrogen ANTAGONIST in others (breast and, importantly, the endometrium, where unlike tamoxifen it does not behave as an agonist). It is FDA-approved for two indications: treatment and prevention of postmenopausal osteoporosis, and reduction of the risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk of breast cancer. Both approvals rest on large randomized trials. The pivotal Multiple Outcomes of Raloxifene Evaluation (MORE) trial randomized 7,705 postmenopausal women with osteoporosis to raloxifene or placebo and showed that raloxifene reduced the risk of new vertebral fractures (RR ~0.7 at 60 mg/day, ~0.5 at 120 mg/day) and increased bone mineral density. The same trial population delivered the breast-cancer signal: invasive breast cancer was reduced by about 70% (RR 0.24 in the first report; 72% by the 4-year analysis), an effect confined to estrogen-receptor-positive disease. The Continuing Outcomes Relevant to Evista (CORE) extension carried that benefit out to 8 years (invasive breast cancer reduced 66%, ER-positive 76% over both trials), and the head-to-head STAR (Study of Tamoxifen and Raloxifene) trial in 19,747 high-risk postmenopausal women found raloxifene roughly equivalent to tamoxifen for preventing invasive breast cancer, with fewer uterine cancers and fewer thromboembolic events than tamoxifen — though it was somewhat less effective against noninvasive (in situ) disease. A 2013 individual-participant meta-analysis of nine SERM prevention trials confirmed the class reduces breast-cancer incidence by ~38% over 10 years. This is genuinely strong, randomized, outcome-level evidence for the approved indications — the strong end of the picture.
The honest counterweight is equally well-documented and is the reason the score sits in the emerging band. The Raloxifene Use for The Heart (RUTH) trial randomized 10,101 postmenopausal women with or at high risk of coronary heart disease to raloxifene or placebo over a median 5.6 years specifically to test a cardiovascular benefit — and found NONE: there was no significant effect on coronary events (hazard ratio 0.95). Worse, raloxifene significantly increased the risk of FATAL STROKE (HR 1.49) and venous thromboembolism — deep-vein thrombosis and pulmonary embolism (HR 1.44) — while again reducing breast cancer and clinical vertebral fractures. So the same tissue-selective agonism that protects bone makes raloxifene pro-thrombotic in the clotting system, exactly as with tamoxifen. Two further hard limits matter: raloxifene reduces VERTEBRAL fractures but has NOT been shown to reduce hip or other non-vertebral fractures (the SERM meta-analysis found only a small, marginal non-vertebral effect), so it is not a complete osteoporosis solution; and it commonly causes hot flushes and leg cramps. Pregnancy is an absolute contraindication.
The off-label male use is the weak end. Because gynecomastia is estrogen-driven and raloxifene antagonizes the estrogen receptor in breast tissue, it has been tried for male breast enlargement. The evidence is thin: the best-known data are a small retrospective pediatric chart review of persistent pubertal gynecomastia in which raloxifene (and tamoxifen) shrank breast-nodule diameter, with raloxifene producing a higher proportion of major responses — but this was 38 boys, retrospective, and the authors themselves flagged that prospective confirmation is needed. There are essentially no controlled trials of raloxifene for adult male gynecomastia, anti-estrogen 'on-cycle' use, or bodybuilding contexts; that use is poorly evidenced and off-label. Overall, raloxifene is a well-proven prescription drug for postmenopausal bone and breast-cancer-risk outcomes whose benefits are real but bounded (no hip-fracture, no cardiovascular benefit) and whose venous-thromboembolic and fatal-stroke risks are documented in its own pivotal trials. It is a prescription SERM, not a dietary supplement, and not a longevity agent.
In bone, raloxifene acts as an estrogen AGONIST — it slows bone resorption and preserves bone mineral density, which is why it reduces vertebral-fracture risk and treats postmenopausal osteoporosis.
In breast tissue raloxifene ANTAGONIZES the estrogen receptor, starving estrogen-driven (ER-positive) tumor growth — the basis for its breast-cancer-risk reduction and its off-label use against estrogen-driven gynecomastia. Unlike tamoxifen, it is NOT an endometrial agonist, so it carries less uterine-cancer risk.
The same tissue-selective estrogen agonism that protects bone makes raloxifene pro-thrombotic — it raises the risk of venous thromboembolism (deep-vein thrombosis, pulmonary embolism) and fatal stroke, documented in its own pivotal trials. This is the mandatory counterweight to the bone and breast benefits.
How Raloxifene (Evista) works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Approved (postmenopausal women) / off-label (male) — clinician-directed. For osteoporosis treatment/prevention and breast-cancer risk reduction the standard, validated dose is 60 mg once daily (the MORE, CORE, RUTH and STAR trials all used 60 mg/day; MORE also tested 120 mg/day with no clear added fracture benefit and more side effects). For off-label male gynecomastia the small published pediatric series used roughly 60 mg/day; there is no FDA-approved male dose and the male evidence is thin and retrospective.
Can be taken without food
| Form | Type |
|---|---|
| 💊Raloxifene hydrochloride 60 mg tablets (approved for postmenopausal osteoporosis and breast-cancer risk reduction) | Recommended |
| 💊Tamoxifen (the prototype SERM — more effective against noninvasive breast cancer but with higher uterine-cancer risk; also used off-label in men) | Alternative |
| 💊Bisphosphonates (alendronate, zoledronate) or denosumab — reduce hip AND vertebral fractures, unlike raloxifene which reduces only vertebral | Alternative |
| 💊Aromatase inhibitors (lower estrogen itself) for breast-cancer prevention in some settings | Alternative |
Raloxifene is a benzothiophene SERM — an estrogen agonist in bone but an antagonist in breast and endometrium (less uterine risk than tamoxifen), while remaining pro-thrombotic in the clotting system.
Compare Raloxifene (Evista) vs Tamoxifen (Nolvadex) →Minimum: 12 weeks
Optimal: 52 weeks
Cycling: Not required
Note: A single 60 mg tablet once daily, with or without food, at any time of day; the osteoporosis and breast-cancer-prevention trials used continuous daily dosing for years. Not a fixed supplement schedule.
Dose-response data unavailable. The current published research for Raloxifene (Evista) does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
In MORE, raloxifene reduced the risk of new vertebral fractures and increased bone mineral density in postmenopausal women with osteoporosis — its core approved indication.
Raloxifene cut invasive ER-positive breast cancer ~70% in MORE, sustained over 8 years in CORE, and roughly matched tamoxifen for prevention in STAR with fewer uterine cancers. Approved for breast-cancer risk reduction in high-risk/osteoporotic postmenopausal women.
The RUTH trial found NO reduction in coronary events, and raloxifene has not been shown to reduce hip or non-vertebral fractures. The benefits are real but bounded — it is not a cardiovascular drug and not a complete osteoporosis solution.
RUTH showed a significant increase in fatal stroke (HR 1.49) and venous thromboembolism — deep-vein thrombosis and pulmonary embolism (HR 1.44). The mandatory honest limit, documented in raloxifene's own pivotal trials.
Hot flushes/vasomotor symptoms and leg cramps are common SERM effects of raloxifene, generally tolerable but frequent enough to affect adherence.
This is the approved population — raloxifene reduces vertebral fractures and invasive ER-positive breast cancer. Weigh the clot/fatal-stroke risk, and note it does NOT reduce hip fractures (a bisphosphonate or denosumab may be preferred if hip-fracture protection is the priority).
Poorly evidenced — the only notable data are a small retrospective pediatric series in persistent pubertal gynecomastia. Off-label, with no controlled trials in adult men; the venous-thromboembolism risk still applies. Use only under medical supervision.
Higher-risk — raloxifene is contraindicated with prior venous thromboembolism and increased fatal stroke in high-CV-risk women in RUTH. Often a poor fit; discuss before use.
Not indicated; contraindicated in pregnancy and breastfeeding (can harm the fetus).
Raloxifene can modestly decrease prothrombin time; monitor INR when starting or stopping. The underlying pro-thrombotic risk of raloxifene also matters in anticoagulated patients.
Cholestyramine reduces raloxifene absorption by about 60% and interrupts its enterohepatic cycling; co-administration is not recommended.
Tip: A documented risk elevated in the pivotal trials (RUTH HR 1.44). Seek urgent care for leg swelling/pain, chest pain, or breathlessness; contraindicated with a prior clot history. Consider stopping before prolonged immobilization.
Tip: RUTH found no increase in overall stroke rate but a significant increase in FATAL stroke (HR 1.49) in women at high cardiovascular risk. Weigh carefully in anyone with stroke risk factors.
Tip: A common SERM effect, often most noticeable early in treatment; usually tolerable.
Tip: Frequently reported; usually mild but can affect adherence.
The commonly studied dose of Raloxifene (Evista) is Approved (postmenopausal women) / off-label (male) — clinician-directed. For osteoporosis treatment/prevention and breast-cancer risk reduction the standard, validated dose is 60 mg once daily (the MORE, CORE, RUTH and STAR trials all used 60 mg/day; MORE also tested 120 mg/day with no clear added fracture benefit and more side effects). For off-label male gynecomastia the small published pediatric series used roughly 60 mg/day; there is no FDA-approved male dose and the male evidence is thin and retrospective.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Timing is flexible for Raloxifene (Evista) — consistent daily use matters more than the time of day. Taken as a single 60 mg oral tablet once daily, with or without food, at any time of day.
Raloxifene (Evista) should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are venous thromboembolism (DVT, pulmonary embolism), fatal / increased-severity stroke, hot flushes / vasomotor symptoms. Use caution if any of these apply to you: Active or past history of venous thromboembolism (deep-vein thrombosis, pulmonary embolism, retinal-vein thrombosis) — raloxifene raises clot risk; Pregnancy and breastfeeding (can harm the fetus; contraindicated); Women of childbearing potential / premenopausal women (not indicated).
A potent non-steroidal aromatase inhibitor (Femara) that blocks estrogen synthesis. Approved for hormone-receptor-positive breast cancer, it is also the evidence-backed first-line drug for ovulation induction in PCOS — where a landmark NEJM RCT showed it BEAT clomiphene on live births. Used off-label in men to raise testosterone and lower estradiol, but that estrogen suppression harms bone and lipids, and in growing boys it carries a vertebral-deformity signal. A prescription drug, not a supplement, and NOT a longevity drug.
Concomitant use with systemic estrogen is not recommended; overlapping or opposing effects on the estrogen axis with other hormonal agents are not well validated.
Tip: Generally mild; discuss with the prescribing clinician if bothersome.